News

The therapy showed majority benefit in viral suppression at nearly 1 year among younger patients.

Trending infectious disease news.

A Harvard Medical School study team sought to identify individuals at elevated risk for severe COVID-19 and, among them, those at high risk of financial ruin as a result of costs associated with their care.

As the lockdown ends, the NIAID director talks the continued need for social distancing, vaccines, and emerging therapies.

Infectious disease experts have recommended that stockpiles of several promising vaccine candidates be created as they enter late stage development.

The novel integrase inhibitor was well tolerated in adult non-HIV infected population.

A brief on today's top ID stories.

Sepsis is characterized by a dysfunctional immune response to infection—norepinephrine can contribute to this immune dysregulation.

The antibacterial is efficacious in a majority of patients in a small study.

A team of investigators present a new solution to an old problem.

Baloxavir marboxil showed superiority over placebo and similar efficacy to oseltamir in reducing influenza symptoms.

A summary of the latest infectious disease news.

COVIDSeq is a qualitative test for the detection of SARS-CoV-2 RNA.

Investigators from the Universitat Autònoma de Barcelona have identified links between antibiotic resistant S maltophilia phenotypes and "quorum sensing."

ChromaCode now intends to use its own multiplexing technology to help launch a COVID-19 assay later this year. The assay would combine multiple respiratory viruses into a single test in anticipation of the upcoming flu season.

Patrick Soon-Shiong, MD, describes goals and expectations for the accelerated coronavirus vaccine program Operation Warp Speed.

Early administration of such therapies in this patient group not shown to help mortality rates.

A brief update on today's infectious disease news.

A review of 61 clinical trials suggests that acute uncomplicated cystitis in adult women could be treated with shorter duration of antibiotics in some cases.

The test uses whole blood, plasma, or serum. The testing kit is intended to produce reliable results within 10 minutes.

Patrick Soon-Shiong, MD, explains why an ImmunityBio SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.

An assessment of 21 pediatric cases leads France investigators to believe development is due to post-viral immunological reactions.

Mild symptoms may still present high risk for SARS-CoV-2 transmission.

A quick brief on today's top infectious disease news.

Due to health concerns, the US FDA is reissuing some EUAs to clarify which respirators are suited for decontamination and reuse.

SARS-CoV-2 arrived in Northern California through a complicated series of introductions internationally and between states.

Mary Schmidt, MD, discusses challenges in translating infectious disease advice to policy action.

An in-depth look at the factors associated with the progression to CDI in colonized patients reveals specific risks that may guide future management of this vulnerable population.

The following is a roundup of the latest ID pipeline developments.

Pinar Karaca-Mandic, PhD, explains new research showing how exponentional rates of hospitalizations were avoided in 4 shut-down states.